Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma by Brochez, Lieve et al.
CORRESPONDENCE
Challenging PD-L1 expressing cytotoxic T cells as a
predictor for response to immunotherapy in
melanoma
Lieve Brochez1,2,3,4, Annabel Meireson2,3, Inès Chevolet2, Nora Sundahl3,5, Piet Ost3,4,5 & Vibeke Kruse3,6
We read with great interest the report by Jacquelot N et al.1 on
‘predictors of responses to immune checkpoint blockade in
advanced melanoma’. Based on an ex vivo metastatic lymph node
assay (stage III, n= 37), the authors conclude that PD-L1
expression on circulating CD4+ and CD8+ T cells might be
predictive biomarkers for resistance to CTLA-4 blockade. These
observations were conﬁrmed in vivo in another patient cohort,
including 190 unresectable stage III and IV melanoma patients
who were treated with ipilimumab.
We would like to report our observation that PD-L1
expressing cytotoxic T cells are associated with an altered
immune climate and a negative impact on disease outcome in
melanoma patients independent of treatment. It therefore
meets the criteria of a prognostic biomarker2. Whether this
biomarker is also predictive for response to immunotherapy—
meaning that the effect of immunotherapy is different in bio-
marker positive and negative patients—cannot be deduced from
the retrospective single-arm (only treated patients) data in the
study by Jacquelot et al. In fact this would require at least a two-
arm design preferably in a randomized study, and known PD-
L1+ cytotoxic T levels in all patients. The only way to permit
solid conclusions on its predictive value would be to demon-
strate that the treatment-by-biomarker interaction is statisti-
cally signiﬁcant, meaning that the levels of PD-L1 cytotoxic
T cells are not only associated with worse disease outcome
(prognostic), but are also associated with different response
reactions to immunotherapy (predictive).
We investigated the in vivo immune proﬁle in a cohort of
55 stage I to III patients having undergone only surgery. The
median follow-up after diagnosis was 61 months (IQR: 38–112).
During follow-up 15 patients (27.3%) experienced disease relapse
and six patients (10.9%) died. Blood sampling for immune pro-
ﬁling was performed at a median time of 15 months (IQR: 4–60)
after diagnosis. Patients’ characteristics are presented in Supple-
mentary Table 1.
The level of PD-L1+ CD8+ cells was strongly correlated with a
number of markers indicating a negative immune climate
(Table 1). In the current study cohort, a high frequency of PD-L1
+ CD8+ cells was associated with decreased plasmacytoid den-
dritic cells (pDCs) and increased myeloid-derived suppressor cells
(MDSCs). We previously demonstrated that these cell types are
inversely correlated and have an independent prognostic effect on
overall survival (OS) in melanoma patients3. Although PD-L1
+ CD8+ cells were negatively correlated with CD4+ cells there
was a strong correlation with Tregs (as detected by CD3+ CD4+
CD25+ FoxP3+ expression) and the number of CTLA-4
expressing Tregs. On the other hand, levels of PD-L1+ CD8+
cells were positively correlated with the serum kynurenine/tryp-
tophan (kyn/trp) ratio, reﬂecting increased functional activity of
indoleamine 2, 3-dioxygenase (IDO) in these patients. The
intracellular enzyme IDO degrades tryptophan to kynurenine
which is considered to be a mechanism attributing to immune
tolerance. IDO has been demonstrated to be a negative prognostic
marker in a variety of cancers4. The above results imply that PD-
L1 expression on cytotoxic T-cells is in close interplay with other
immune-inhibitory cell types and molecules, all together con-
tributing to the installation of a negative immune climate.
The clinical follow-up of the included patients is illustrated in
Fig. 1a. Patients who died from melanoma (n= 6; median time of
9.5 months after blood sampling, IQR: 3.8–28.8) had higher levels
of PD-L1+ CD8+ cells (p= 0.039, Mann–Whitney U-test). For
survival analysis, the percentage of circulating PD-L1+ CD8+
cells was dichotomized by ROC analysis into “low” (<0.1505% of
live PBMCs) and “high” (>0.1505% of live PBMCs). High levels of
PD-L1+ CD8+ cells were observed to be a negative prognostic
marker for OS in univariate analysis (p= 0.038, log-rank test,
Fig. 1b). Multivariate analysis with a Cox proportional hazard
regression model including disease stage (local versus regional
disease) demonstrated PD-L1+ CD8+ cells to be an independent
negative prognostic marker on OS (p= 0.047; HR: 7.42, 95% CI:
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1.03–53.67). Moreover, the frequency of PD-L1+ CD8+ cells was
increased in patients who were close to disease relapse or disease
related death. The shorter the time frame between blood sampling
and relapse or death, the higher the frequency of PD-L1+ CD8+
cells (resp. p= 0.005, CC −0.975 and p= 0.005, CC −0.943).
Jacquelot et al. state that prediction of patients’ response to
immunotherapy by dynamic biomarkers represent an unmet
medical need. More important than ﬁnding predictors for
immunotherapy (no-) response may be the development of tools
to routinely monitor the immune response before and during
immunotherapy. If negative immunological signs are observed,
there might be an opportunity for early intervention to try to
reverse this climate. In 10 stage IV melanoma patients treated
with ipilimumab and stereotactic body radiotherapy, non-
responders showed an increase in the kyn/trp ratio during
treatment compared to baseline5. Wang et al.6 recently demon-
strated that increasing kyn/trp ratio after chemoradiation predicts
worse survival outcome in lung cancer patients. As the kyn/trp
ratio is reﬂecting IDO activity, these patients subgroups might be
candidates for an IDO-inhibitor.
Immunomonitoring before and during cancer (immuno-)
therapy, and sequential therapy adapted to the observations—
rather than upfront combinations—may be a new step in the era
of personalized immunotherapy.
Methods
Patients. Fifty-ﬁve patients with melanoma were included in this study, with a
median follow-up of 61 months (38.0–112.0) after diagnosis and 46 months
(22.0–55.0) after inclusion (i.e., the time of blood collection). Only patients who did
not receive systemic therapy were included, to avoid any possible inﬂuence on
marker expression and survival analysis. Detailed patient characteristics can be
found in Supplementary Table 1. This study was approved by the ethical committee
of Ghent University Hospital. All included patients provided informed consent
before enrollment in the study.
PBMC isolation. Peripheral blood mononuclear cells (PBMCs) were isolated from
heparinized venous blood by centrifugation on a Ficoll-Hypaque gradient (GE
Healthcare, Uppsala, Sweden) within a 4 h of venipuncture. The cells were washed
three times and cryopreserved at −80 °C in fetal bovine serum (FBS, Invitrogen,
Merelbeke, Gelbium) supplemented with 10% dimethyl sulfoxide (DMSO, Merck,
Darmstadt, Germany) and 1% penicillin-streptavidine (Invitrogen, Merelbeke,
Belgium) until analysis. Cells were thawed by submersion at 37° for 1–2 min and
resuspended in a medium containing Iscove’s Modiﬁed Dulbeco’s Medium
(IMDM) supplemented with 20% FBS and 1% glutamine.
Flow cytometry. MDSCs were characterized by the HLA-DR– lineage– (CD3,
CD19, and CD56) CD33+ CD11b+ phenotype. Dendritic cells were characterized
by the HLA-DR+ lineage– (CD3, CD14, CD16, CD19, CD20, and CD56) pheno-
type, pDCs are CD123+ CD11c‒. Tregs were deﬁned as CD3+ CD4+ CD25+
FoxP3+ and cytotoxic T-cells as CD3+ CD8+ cells. All antibodies used in this
study were ﬂuorescently conjugated mouse anti-human monoclonal antibodies.
The following antibodies were purchased from BD Biosciences; CD3 BV421
(563797), CD4 APC-Cy7 (561839), CD25 FITC (560990), CD33 BV421 (562854),
CD11b APC-Cy7 (560914), CD123 BV421 (562517). The following antibodies
were purchased from eBioscience; B7-H1 PE-Cy7 (25-5983-42), CD8 APC (9017-
0087-025), CD3 FITC (11-0038-41), CD19 FITC (11-0199-41), CD56 FITC (11-
0569-41), CD14 APC (17-0149-41), CD11c APC (17-0116-41), HLA-DR PerCP-
Cy5.5 (45-9956-42). For intracellular stainings, after surface staining PBMCs were
ﬁxed and permeabilized with ﬁxation⁄permeabilization solution (BD Biosciences),
and then stained with CTLA-4 APC (BD Biosciences, 560938) and FoxP3 PerCP-
Cy5.5 (eBioscience, 45-4776-42) antibodies. Live/dead staining was performed
using Live/dead® ﬁxable aqua dead cell stain (Life Technologies Europe). Cells were
analyzed on a FACSCanto™ II ﬂow cytometer (BD Bioscience, Erembodegem,
Belgium) using FlowJo software (Tree Star Inc, Ashland, OR, USA). For setting the
gates, isotype, and ﬂuorescence-minus-one (FMO) controls were used. To provide
a representative sample a median amount of 500,000 cells was analysed per cell
type (min 261,000–max 569,750). The reported frequencies of circulating cell types
are percentages of live PBMCs, except for Treg frequencies which are percentages
of CD4+ cells.
Ultra-performance liquid chromatography (UPLC). UPLC-MS/MS (Waters
Acquity TQD) was conducted to quantify tryptophan and kynurenin on frozen
patient sera, according to previously published methods7.
Statistical analysis. All statistical analyses were performed using SPSS 24.0 (SPSS
Inc, Chicago, IL, USA), a P-value less than 0.05 was considered statistically sig-
niﬁcant (double-sided). Shapiro-Wilk test demonstrated that the data had no
normal distribution and therefore non-parametric statistical tests were used for
further analysis. Spearman correlation coefﬁcients (CC) were calculated to evaluate
correlations between continuous variables.. Values between two groups were
compared by a two-tailed Mann–Whitney U-test. OS was estimated by the
Table 1 Association of PD-L1+ CD8+ cells with other
systemic immune markers
Spearman correlation coefﬁcient P-value
Serum
Kyn/Trp 0.339 0.014
PBMCs: T-lymphocytes
CD3+ 0.367 0.006
CD4+ −0.446 0.001
Tregs 0.414 0.002
CTLA-4+ Tregs 0.399 0.003
CD8+ −0.589 <0.001
PBMCs: dendritic cells
MDSC/pDC 0.304 0.024
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Fig. 1 PD-L1+ CD8+ level according to disease stage and overall survival. Swimmer plot showing the relation between the ranking of PD-L1+ CD8+ cells
(according to frequency) and clinical follow-up. b Kaplan–Meier curves of overall survival according to the levels of PD-L1+CD8+ cells (% of live peripheral
blood mononuclear cells)
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Kaplan–Meier method and compared by the log-rank test. OS was deﬁned as the
time from the date of blood collection to death. Multivariate survival analysis was
performed utilizing the Cox proportional hazard model. Dichotomization of the
level of PD-L1+ CD8+ cells was performed by means of ROC analysis maximizing
Youden’s statistics using R software. A value of 0.1505% was set as a cut-off
(sensitivity 91.7%, speciﬁcity 48.3%).
Data availability. The dataset generated during and/or analysed for the current
study are available from the corresponding author on reasonable request.
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